Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Adenosine SPECT myocardial perfusion imaging Clear all
Terminated Phase 3 Interventional

A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography

NCT00162084
View directory record Official record
Conditions
Heart Disease, Ischemic Heart Disease
Interventions
apadenoson
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • North Little Rock, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 30, 2026, 5:50 AM EDT
Terminated Phase 4 Interventional

Both Exercise and Adenosine Stress Testing

NCT00200629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging
Procedure
Lead sponsor
Midwest Heart Foundation
Other
Eligibility
60 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
20
States / cities
Tucson, Arizona • Roseville, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2011 · Synced Sep 30, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158

NCT00849108
View directory record Official record
Conditions
Ischemia
Interventions
BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Fremont, California • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 30, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208299
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Sep 30, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT00990327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Sep 30, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Sep 30, 2026, 5:50 AM EDT
Terminated Phase 3 Interventional

A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.

NCT00380198
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Timeline
2006
U.S. locations
42
States / cities
Huntsville, Alabama • Santa Rosa, California • Bridgeport, Connecticut + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 30, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain

NCT00705458
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris, Unstable Angina, Acute Coronary Syndrome
Interventions
Coronary Computed Tomography Angiography, Stress Nuclear Myocardial Perfusion Imaging
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 30, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT03354273
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
PET MPI, SPECT MPI, Pharmacological stress agents
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Sep 30, 2026, 5:50 AM EDT
Completed No phase listed Observational

Adenosine Dual Source Computed Tomography (CT) Versus Adenosine Single Photon Emission Computed Tomography (SPECT)

NCT00892307
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement
Radiation
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 30, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208312
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2009 · Synced Sep 30, 2026, 5:50 AM EDT